MX2022014909A - Tratamiento del cáncer. - Google Patents
Tratamiento del cáncer.Info
- Publication number
- MX2022014909A MX2022014909A MX2022014909A MX2022014909A MX2022014909A MX 2022014909 A MX2022014909 A MX 2022014909A MX 2022014909 A MX2022014909 A MX 2022014909A MX 2022014909 A MX2022014909 A MX 2022014909A MX 2022014909 A MX2022014909 A MX 2022014909A
- Authority
- MX
- Mexico
- Prior art keywords
- cancer
- treatment
- breast cancer
- subject
- chemotherapy
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract 3
- 201000011510 cancer Diseases 0.000 title abstract 3
- 206010006187 Breast cancer Diseases 0.000 abstract 1
- 208000026310 Breast neoplasm Diseases 0.000 abstract 1
- 229940124297 CDK 4/6 inhibitor Drugs 0.000 abstract 1
- 102000017578 LAG3 Human genes 0.000 abstract 1
- 101150030213 Lag3 gene Proteins 0.000 abstract 1
- 229940123237 Taxane Drugs 0.000 abstract 1
- 238000002512 chemotherapy Methods 0.000 abstract 1
- 239000012829 chemotherapy agent Substances 0.000 abstract 1
- 208000027706 hormone receptor-positive breast cancer Diseases 0.000 abstract 1
- 208000026534 luminal B breast carcinoma Diseases 0.000 abstract 1
- 210000001616 monocyte Anatomy 0.000 abstract 1
- DKPFODGZWDEEBT-QFIAKTPHSA-N taxane Chemical class C([C@]1(C)CCC[C@@H](C)[C@H]1C1)C[C@H]2[C@H](C)CC[C@@H]1C2(C)C DKPFODGZWDEEBT-QFIAKTPHSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Marine Sciences & Fisheries (AREA)
- Cell Biology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
Abstract
Esta invención se relaciona con el uso de una proteína LAG-3 o un derivado de esta y opcionalmente un agente de quimioterapia para el tratamiento del cáncer en un sujeto. El sujeto puede tener uno o más de un recuento de monocitos bajo, un cáncer de mama Luminal B, una edad menor que aproximadamente 85 años, se ha tratado previamente con un inhibidor de CDK4/6, y no se ha sometido previamente a tratamiento con una quimioterapia con taxanos. Adecuadamente, el cáncer es un cáncer de mama, tal como un cáncer de mama positivo para el receptor de hormonas.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB2008037.0A GB202008037D0 (en) | 2020-05-28 | 2020-05-28 | Treatment of cancer |
| RU2020131384A RU2020131384A (ru) | 2020-05-28 | 2020-09-23 | Лечение рака |
| GBGB2018062.6A GB202018062D0 (en) | 2020-11-17 | 2020-11-17 | Treatment of cancer |
| PCT/EP2021/057588 WO2021239292A1 (en) | 2020-05-28 | 2021-03-24 | Treatment of cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2022014909A true MX2022014909A (es) | 2023-03-06 |
Family
ID=75362569
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022014909A MX2022014909A (es) | 2020-05-28 | 2021-03-24 | Tratamiento del cáncer. |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20230210946A1 (es) |
| EP (1) | EP4157313A1 (es) |
| JP (1) | JP2023527209A (es) |
| KR (1) | KR20230028321A (es) |
| CN (1) | CN116133674A (es) |
| AU (1) | AU2021280214A1 (es) |
| BR (1) | BR112022024179A2 (es) |
| CA (1) | CA3184309A1 (es) |
| IL (1) | IL298507A (es) |
| MX (1) | MX2022014909A (es) |
| WO (1) | WO2021239292A1 (es) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2023152335A1 (en) * | 2022-02-11 | 2023-08-17 | Immutep S.A.S. | Treatment of cancer |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2044949A1 (en) | 2007-10-05 | 2009-04-08 | Immutep | Use of recombinant lag-3 or the derivatives thereof for eliciting monocyte immune response |
| WO2020047329A1 (en) * | 2018-08-29 | 2020-03-05 | Shattuck Labs, Inc. | Chimeric proteins comprising extracellular domains and uses thereof |
-
2021
- 2021-03-24 CA CA3184309A patent/CA3184309A1/en active Pending
- 2021-03-24 MX MX2022014909A patent/MX2022014909A/es unknown
- 2021-03-24 JP JP2022573285A patent/JP2023527209A/ja active Pending
- 2021-03-24 KR KR1020227046217A patent/KR20230028321A/ko unknown
- 2021-03-24 IL IL298507A patent/IL298507A/en unknown
- 2021-03-24 WO PCT/EP2021/057588 patent/WO2021239292A1/en unknown
- 2021-03-24 CN CN202180059063.2A patent/CN116133674A/zh active Pending
- 2021-03-24 EP EP21716087.8A patent/EP4157313A1/en active Pending
- 2021-03-24 US US17/928,048 patent/US20230210946A1/en active Pending
- 2021-03-24 AU AU2021280214A patent/AU2021280214A1/en active Pending
- 2021-03-24 BR BR112022024179A patent/BR112022024179A2/pt unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP4157313A1 (en) | 2023-04-05 |
| BR112022024179A2 (pt) | 2023-02-07 |
| CN116133674A (zh) | 2023-05-16 |
| WO2021239292A1 (en) | 2021-12-02 |
| JP2023527209A (ja) | 2023-06-27 |
| CA3184309A1 (en) | 2021-12-02 |
| AU2021280214A1 (en) | 2023-02-02 |
| IL298507A (en) | 2023-01-01 |
| US20230210946A1 (en) | 2023-07-06 |
| KR20230028321A (ko) | 2023-02-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2022007515A (es) | Inhibidores de sos1. | |
| MX2022005360A (es) | Inhibidores de ras. | |
| CR20220241A (es) | Inhibidores de ras | |
| MX2022001075A (es) | Compuestos para usarse en el tratamiento de cancer de mama que expresa el receptor de androgenos (ar+). | |
| MX2021002998A (es) | Compuestos de triazolo-pirimidina y usos de los mismos. | |
| WO2019067666A8 (en) | Therapeutic methods relating to hsp90 inhibitors | |
| ZA201907225B (en) | Treatment of her2 positive cancers | |
| TN2010000204A1 (en) | Kinesin inhibitors as cancer therapeutics | |
| MX2021012501A (es) | Inhibidores de complejo represivo polycomb 2 (prc2). | |
| CR20230570A (es) | Inhibidores de ras | |
| PH12021551036A1 (en) | Anti-liv1 immune cell cancer therapy | |
| MX2022000310A (es) | Inhibidores de proteina bcl-2. | |
| PH12021550620A1 (en) | Ophthalmic composition for treatment of dry eye disease | |
| MX2021013901A (es) | Composiciones y métodos para el tratamiento del cáncer. | |
| JOP20210164A1 (ar) | طرق وتركيبات علاج السرطان | |
| PH12019502086A1 (en) | Deuterated imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer | |
| PH12020552286A1 (en) | Compositions and methods for treating inflammasome related diseases or conditions | |
| MX2022014909A (es) | Tratamiento del cáncer. | |
| WO2017136731A8 (en) | Rapaglutins, novel inhibitors of glut and use thereof | |
| BR112022012867A2 (pt) | Tratamento de câncer com inibidores de cdk12/13 | |
| NZ762312A (en) | Anti-pacap antibody | |
| MX2021002652A (es) | Uso de inhibidores de caseina-cinasa 1 para el tratamiento de enfermedades vasculares. | |
| MX2020011377A (es) | Metodos y composiciones para el tratamiento de urticaria cronica. | |
| MX2021002818A (es) | Métodos para tratar el cáncer mediante la inhibición de la enzima conjugadora de ubiquitina e2 k (ube2k). | |
| MX2022001411A (es) | Metodos para tratar o prevenir canceres que implican la administracion de agentes receptores anti-ccr5. |